AstraZeneca PLC shares plunged after weekend reports that the company held preliminary merger discussions with U.S. rival Bristol Myers Squibb. The stock fell 6.9% to trade at 11,762 pence following coverage by the Financial Times, Bloomberg, and Reuters that said the combination would create a combined entity valued at nearly $400 billion.
The disclosure prompted an immediate sell-off in London trading - a common market response when a large-cap company is linked to a potential transformational acquisition. Market participants moved to reprice AstraZeneca’s equity as investors digest the potential implications of a near-$400 billion deal.
Analysts and investors highlighted that the proposed tie-up would entail significant execution risk. Both companies operate major oncology businesses, producing substantial overlap between their drug portfolios. That overlap is expected to attract close scrutiny from U.S. antitrust authorities under the current administration, which could complicate and prolong any approval process.
Details on how a transaction would be structured have not been settled. Reports indicate the deal would likely involve a mix of cash and shares, which raises the possibility of meaningful dilution for existing AstraZeneca shareholders. The combination of a sizable deal premium, potential dilution, and antitrust concerns contributed to the sharp negative reaction in AstraZeneca’s stock.
The prospect of drawn-out negotiations or talks that fail to reach a finalized agreement also adds to near-term uncertainty over the share price. Reports cautioned that discussions are preliminary, and negotiations could be delayed or break down entirely, leaving investors to weigh outcomes ranging from a negotiated deal to no transaction at all.
Despite AstraZeneca’s company-specific weakness, the wider market environment that day was relatively constructive. London’s FTSE 100 edged down just 0.1%, continental European indices posted solid gains, and U.S. futures pointed higher with the S&P 500 up 0.5% and the NASDAQ higher by 0.7%.
The contrast between AstraZeneca’s steep decline and general market strength underlines that the move was driven by the merger headline rather than broader macro or sector pressure. Intraday pricing data also reflected the drop, with a recent quote shown at 11,798.00 - down 832.0, or roughly 6.59% on one intraday snapshot.
Prior to the sell-off, AstraZeneca had been supported by company fundamentals, including a reconfirmed 2026 earnings guidance and a bullish analyst view from Bernstein, which raised its price target to GBp 20,200. Even with those positive elements in place, the merger-related concerns pushed the shares to their lowest intraday levels since earlier in the year.
Market context: The fall in AstraZeneca’s shares reflected deal-premium concerns, antitrust risk, and the potential for shareholder dilution. These factors outweighed recent company-level positives and sent the stock materially lower amid otherwise constructive market conditions.